Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
Public ClinicalTrials.gov record NCT02962414. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multi-center Long-term Safety Roll-over Study in Patients With Tuberous Sclerosis Complex (TSC) and Refractory Seizures Who Are Judged by the Investigator to Benefit From Continued Treatment With Everolimus After Completion of Study CRAD001M2304.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the long-term safety in patients with TSC and refractory seizures who are currently receiving everolimus treatment in the Novartis-sponsored EXIST-3 study and who are determined to be benefiting from continued treatment as judged by the investigator at the completion of EXIST-3
Study identification
- NCT ID
- NCT02962414
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 206 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 2 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 22, 2017
- Primary completion
- Dec 29, 2026
- Completion
- Dec 29, 2026
- Last update posted
- Aug 20, 2026
2017 – 2026
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| TGen APNNA | Phoenix | Arizona | 85012 | — |
| David Geffen School of Medicine at UCLA | Los Angeles | California | 90005-1752 | — |
| UCSF Benioff Children s Hospital | Oakland | California | 94609 | — |
| Rady Children s Hospital | San Diego | California | 92123 | — |
| University of Colorado School of Medicine | Aurora | Colorado | 80045 | — |
| Connecticut Childrens Medical Cntr | Hartford | Connecticut | 06106 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Minnesota Epilepsy Group | Saint Paul | Minnesota | 55102 | — |
| Atlantic Health Morristown MC | Morristown | New Jersey | 07962 | — |
| Cinn Children Hosp Medical Center | Cincinnati | Ohio | 45229-3039 | — |
| Oregon Health Sciences University | Portland | Oregon | 97239 | — |
| Childrens Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | — |
| Texas Scottish Rite Hos for Child | Dallas | Texas | 75219 | — |
| Texas Childrens Hospital | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02962414, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 20, 2026 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02962414 live on ClinicalTrials.gov.